Cargando…

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients

BACKGROUND: The efficacy of direct-acting antiviral agents (DAAs) could be attenuated by the presence of resistance-associated variants (RAVs). The aim of this study was to investigate the natural prevalence of RAVs among Chinese HCV genotype 1b patients and analyze the efficacy of pegylated interfe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu, Cao, Ying, Zhang, Renwen, Zhang, Xiaxia, Lu, Haiying, Wu, Chihong, Huo, Na, Xu, Xiaoyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094756/ https://www.ncbi.nlm.nih.gov/pubmed/27812165 http://dx.doi.org/10.1371/journal.pone.0165658

Ejemplares similares

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
por: Rizk, Hanan H., et al.
Publicado: (2016)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV
por: Lin, Chia-Chen, et al.
Publicado: (2017)

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
por: Menard, Amélie, et al.
Publicado: (2012)

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients
por: Rivero-Juarez, Antonio, et al.
Publicado: (2014)

Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2015)

Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
por: Jia, Zhifang, et al.
Publicado: (2012)

Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2014)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
por: Chehl, Navdeep, et al.
Publicado: (2019)

Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study
por: Lin, Chih Ying, et al.
Publicado: (2020)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
por: De Francesco, Maria Antonia, et al.
Publicado: (2022)

Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment
por: Sidorkiewicz, Malgorzata, et al.
Publicado: (2020)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
por: Izumi, Namiki, et al.
Publicado: (2012)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
por: Baumgarten, A, et al.
Publicado: (2010)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
por: Tayyab, Ghias Un Nabi, et al.
Publicado: (2020)

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
por: Márquez-Coello, Mercedes, et al.
Publicado: (2021)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
por: Flynn, Jacqueline K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1jini760mnt45c05ge73gafjqi